CASI Pharmaceuticals Current Financial Leverage

CASI
 Stock
  

USD 1.95  0.02  1.02%   

CASI Pharmaceuticals' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. CASI Pharmaceuticals' financial risk is the risk to CASI Pharmaceuticals stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Continue to the analysis of CASI Pharmaceuticals Fundamentals Over Time.
  
CASI Pharmaceuticals Debt Non Current is most likely to increase significantly in the upcoming years. The last year's value of Debt Non Current was reported at 1.72 Million. The current Long Term Debt to Equity is estimated to increase to 0.06, while Issuance Repayment of Debt Securities is projected to decrease to (861.1 K).

CASI Pharmaceuticals Current Financial Burden

CASI Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. CASI Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps CASI Pharmaceuticals Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect CASI Pharmaceuticals' stakeholders.

Asset vs Debt

Equity vs Debt

For most companies, including CASI Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running CASI Pharmaceuticals the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
non Currrent Assets Other
2.2 M
Price Book
0.42
other Assets
2.2 M
liabilities And Stockholders Equity
114.8 M
total Assets
138.3 M
Operating Margin
(0.89) 
Given the importance of CASI Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of CASI Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of CASI Pharmaceuticals to issue bonds at a reasonable cost.

CASI Pharmaceuticals Financial Leverage Rating

CASI Pharmaceuticals bond ratings play a critical role in determining how much CASI Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for CASI Pharmaceuticals' borrowing costs.
Piotroski F Score
3  Frail
Beneish M Score

CASI Pharmaceuticals Debt to Cash Allocation

As CASI Pharmaceuticals follows its natural business cycle, the capital allocation decisions will not magically go away. CASI Pharmaceuticals' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 2.9 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. CASI Pharmaceuticals has a current ratio of 3.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CASI Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, CASI Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CASI Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CASI Pharmaceuticals to invest in growth at high rates of return. When we think about CASI Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

CASI Pharmaceuticals Inventories Over Time

CASI Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which CASI Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

CASI Pharmaceuticals Debt Ratio

    
  0.82   
It seems as most of the CASI Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the CASI Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of CASI Pharmaceuticals, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a CASI Pharmaceuticals debt ratio should be compared their industry average or other competing firms.
Share Download
Share Download

CASI Pharmaceuticals Historical Liabilities

While analyzing the current debt level is an essential aspect of forecasting the current year budgeting needs of CASI Pharmaceuticals, understanding its historical liability is critical in projecting CASI Pharmaceuticals' future earnings, especially during periods of low and high inflation and deflation. Many analysts look at the trend in assets and liabilities and evaluate how CASI Pharmaceuticals uses its financing power over time.
In order to fund their growth, businesses such as CASI Pharmaceuticals widely use Financial Leverage. For most companies, financial capital is raised by issuing debt securities and by selling common stock. The debt and equity that make up CASI Pharmaceuticals' capital structure have many risks and return implications. Leverage is an investment strategy of using borrowed money to increase the potential return of an investment. Please note, the concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Understaning CASI Pharmaceuticals Use of Financial Leverage

CASI Pharmaceuticals financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures CASI Pharmaceuticals's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of CASI Pharmaceuticals assets, the company is considered highly leveraged. Understanding the composition and structure of overall CASI Pharmaceuticals debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it.
Last ReportedProjected for 2022
Total Debt1.2 M1.2 M
Debt Current1.2 M1.2 M
Debt Non Current1.7 M1.8 M
Issuance Repayment of Debt Securities-839 K-861.1 K
Long Term Debt to Equity 0.0447  0.06 
Debt to Equity Ratio 0.0116  0.0119 
Please read more on our technical analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CASI Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CASI Pharmaceuticals' short interest history, or implied volatility extrapolated from CASI Pharmaceuticals options trading.

Pair Trading with CASI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CASI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CASI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with CASI Pharmaceuticals

+0.65ARWRArrowhead Pharmaceuticals Upward RallyPairCorr
+0.85BEAMBeam TherapeuticsInc Normal TradingPairCorr

Moving against CASI Pharmaceuticals

-0.63JNJJohnson Johnson TrendingPairCorr
-0.51JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to CASI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CASI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CASI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CASI Pharmaceuticals to buy it.
The correlation of CASI Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CASI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CASI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CASI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of CASI Pharmaceuticals Fundamentals Over Time. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.8 M
Quarterly Revenue Growth YOY
0.26
Return On Assets
(0.15) 
Return On Equity
(0.27) 
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.